Birgitta Versluijs

86 Results TABLE 2. Pulmonary function test before hematopoietic cell transplantation. Total N=83 Mean difference from reference population (1-sided t -test) Immune deficiency N=13 Malignant disease pretreated with chemotherapy N=41 Bone marrow disease, inborn errors of metabolism no pretreatment N=29 Differences between disease groups (ANOVA) FEV1 (% pred) 82.7 (11.5) -17.3 (95% CI: -20.5-14.1) P <.0001 83.5 (12.9) 81.3 (10.1) 84.3 (12.6) NS FVC (% pred) 87.8 (14.1) -12.2 (95% CI: -16.2-8.2) P <.0001 91.5 (14.6) 86.3 (12.7) 88.1 (15.7) NS TLC (% pred) 86.9 (10.2) -14.5 (95% CI: -17.9-11.1) P <.0001 92.2 (8.3) 83.8 (10.8) 84.5 (7.6) NS RV/TLC 25.2 (5.7) 25.4 (5.8) 23.6 (4.9) 27.5 (6.0) NS TLCO (% pred) 81.9 (18.5) -18 (95% CI: -25.8-10.4) P <.0001 85.7 (21.6) 81.0 (19.8) 81.2 (13.2) Abnormal PFT* 8 (62) 28 (68) 19 (65) * Abnormal PFT defined as <80% pred or RV/TLC > 25, data are numbers (percentage). FEV1 indicates forced expiratory volume in 1 second; % pred, percentage of predicted value; 95% CI, 95% confidence interval; NS, not significant; FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; TLCO, lung diffusion capacity for CO. Mean values and SD in all patients, compared with reference population, mean values and SD per disease group, and comparison between disease groups. 5